🔎 Trials Near Me

Home › Metastatic Cancer › California › San Francisco

Pag-aaral pangklinika para sa Metastatic Cancer sa San Francisco, CA

Isang pag-aaral para sa Metastatic Cancer ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa San Francisco. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

Nagre-recruitPhase 1/2
  • Avenzo Therapeutics Recruiting Site, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT07193511

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

Nagre-recruitPhase 1/2
  • University of California San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05287945

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Nagre-recruitPhase 3
  • UCSF at China Basin, San Francisco
  • UCSF at Mount Zion, San Francisco
  • UCSF at Parnassus, San Francisco
  • at 1 pa
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07222800

Intratumoral N17350 in Advanced Solid Tumors

Nagre-recruitPhase 1/2
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07339176

Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

Nagre-recruitPhase 1
  • UCSF Medical Center at Mount Zion, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT06915753

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

Nagre-recruitPhase 3
  • UCSF Medical Center at Mission Bay, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07218380

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Nagre-recruitPhase 3
  • Kaiser Permanente, San Francisco
  • UCSF Medical Center at Mission Bay, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07174336

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Nagre-recruitPhase 1/2
  • UCSF Medical Center at Mission Bay ( Site 0034), San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT06863272

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Nagre-recruitPhase 1/2
  • University of California, San Francisco (UCSF), San Francisco
Edad 18 pataas · Kababaihan · Na-update Set 3, 2026 · NCT04802759

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Nagre-recruitPhase 1
  • University of California San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT04913285

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Nagre-recruitPhase 1/2
  • University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05919264

A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Nagre-recruitPhase 1/2
  • Crinetics Study Site, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT07129252

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Nagre-recruitPhase 2
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT07043608

Imaging of Solid Tumors Using 18F-TRX

Nagre-recruitPhase 1
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT06942104

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Nagre-recruitPhase 1/2
  • UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 12 pataas · Lahat ng kasarian · Na-update Hul 14, 2026 · NCT05533697

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Nagre-recruitPhase 1
  • University of California San Francisco, San Francisco
Edad 18 pataas · Kalalakihan · Na-update Hul 9, 2026 · NCT07103018

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Nagre-recruitPhase 1
  • Exelixis Clinical Site #5, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT06952010

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Nagre-recruitPhase 1
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 18, 2026 · NCT05694715

Imaging of Solid Tumors Using FAP-2286

Nagre-recruitPhase 1
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 4, 2026 · NCT04621435

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

Nagre-recruitPhase 1
  • University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 2, 2026 · NCT06917079

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

Nagre-recruitPhase 1/2
  • University of California San Francisco (UCSF), San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 28, 2026 · NCT06413680

Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma

Nagre-recruitPhase 2/3
  • University of California San Francisco - Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 17, 2026 · NCT06947928

Comparison of Whole Body DWI to FDG PET

Nagre-recruit
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 3, 2026 · NCT06630845

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

Nagre-recruitPhase 1/2
  • University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer Center, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 18, 2026 · NCT06244771

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Nagre-recruitPhase 1
  • University of California San Francisco-Benioff Children's Hospital, San Francisco
Edad 1 hanggang 40 · Lahat ng kasarian · Na-update Mar 12, 2026 · NCT05292664

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Nagre-recruitPhase 1
  • University of California San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT06778863

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Nagre-recruitObservasyonal na pag-aaral
  • Massive Bio SYNERGY-AI site, San Francisco
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

A Study of NX-1607 in Adults With Advanced Malignancies

Nagre-recruitPhase 1
  • University of California, San Francisco, San Francisco
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT05107674

Pag-aaral para sa Metastatic Cancer sa ibang lungsod

Iba pang pag-aaral sa San Francisco

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.